---
layout: post
title: "Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments; Public Meeting; Request for Comments"
date: 2026-02-05 19:09:02 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2024-07493
original_published: 2024-04-09 00:00:00 +0000
significance: 8.00
---

# Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments; Public Meeting; Request for Comments

**Published:** February 05, 2026 19:09 UTC
**Source:** Federal Register
**Original Published:** April 09, 2024 00:00 UTC
**Document Number:** 2024-07493

## Summary

The Food and Drug Administration (FDA or the Agency) is announcing the following public meeting entitled "Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments." The topic to be discussed is the financial transparency and efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2024/04/09/2024-07493/financial-transparency-and-efficiency-of-the-prescription-drug-user-fee-act-biosimilar-user-fee-act)
- API: https://www.federalregister.gov/api/v1/documents/2024-07493

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
